For citations:
Abdullaev Sh.P., Bure I.V., Shatokhin M.N., Abdullaev Sh.P., Bochkov P.O., Tuchkova S.N., Mirzaev K.B., Loran O.B., Sychev D.A. Impact of CYP3A4*22 Genetic Variant and Plasma microRNA mir-27b Expression Level on Silodosin Steady-State Concentration and Therapy Outcomes in Patients with Benign Prostatic Hyperplasia: A Prospective Observational Trial. Pharmacy & Pharmacology. 2025;13(6):487-499. (In Russ.) https://doi.org/10.19163/2307-9266-2025-13-6-487-499


















































